Arcus Biosciences, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Arcus Biosciences, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2017 to Q2 2024.
  • Arcus Biosciences, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $20M, a 11.1% increase year-over-year.
  • Arcus Biosciences, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $76M, a 8.57% increase year-over-year.
  • Arcus Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $73M, a 12.3% increase from 2022.
  • Arcus Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $65M, a 18.2% increase from 2021.
  • Arcus Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $55M, a 150% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $76M $20M +$2M +11.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $74M $20M +$1M +5.26% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $73M $18M +$1M +5.88% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-21
Q3 2023 $72M $18M +$2M +12.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $70M $18M +$3M +20% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $67M $19M +$2M +11.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $65M $17M +$2.71M +19% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-21
Q3 2022 $62.3M $16M +$1.42M +9.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $60.9M $15M +$1.63M +12.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $59.2M $17M +$4.24M +33.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $55M $14.3M +$6.22M +77.1% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-21
Q3 2021 $48.8M $14.6M +$8.58M +143% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 $40.2M $13.4M +$8.9M +199% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 $31.3M $12.8M +$9.3M +269% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $22M $8.07M Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 $6M +$3.26M +119% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $4.47M +$2.34M +110% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $3.46M +$1.79M +107% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q3 2019 $2.74M +$1.69M +161% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $2.13M +$1.01M +90.9% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $1.67M +$1.02M +155% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
Q3 2018 $1.05M +$912K +671% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 $1.12M +$985K +752% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $656K +$584K +811% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q3 2017 $136K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $131K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-06
Q1 2017 $72K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.